Novel hepato‐preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes

Basal insulin peglispro (BIL) is a novel PEGylated basal insulin with a flat pharmacokinetic and glucodynamic profile and reduced peripheral effects, which results in a hepato‐preferential action. In Phase 3 trials, patients with T1DM treated with BIL had lower prandial insulin requirements, yet improved prandial glucose control, relative to insulin glargine (GL). We hypothesized that this may be because of an enhanced sensitivity to prandial insulin with BIL resulting from lower chronic peripheral insulin action.

[1]  J. M. Beals,et al.  Basal insulin peglispro: Overview of a novel long‐acting insulin with reduced peripheral effect resulting in a hepato‐preferential action , 2016, Diabetes, obesity & metabolism.

[2]  S. Garg,et al.  A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1 , 2016, Diabetes, obesity & metabolism.

[3]  J. Bue-Valleskey,et al.  Basal insulin peglispro versus insulin glargine in insulin‐naïve type 2 diabetes: IMAGINE 2 randomized trial , 2016, Diabetes, obesity & metabolism.

[4]  F. Travert,et al.  Randomized, double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3 , 2016, Diabetes, obesity & metabolism.

[5]  M. Andjelkovic,et al.  Aleglitazar, a dual peroxisome proliferator‐activated receptor‐α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double‐blind trial , 2016, Diabetes, obesity & metabolism.

[6]  A. Chang,et al.  Randomized double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4 , 2016, Diabetes, obesity and metabolism.

[7]  A. Chang,et al.  Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5 , 2015, Diabetes Care.

[8]  O. Dekkers,et al.  Insulin resistance in patients with type 1 diabetes assessed by glucose clamp studies: systematic review and meta-analysis. , 2015, European journal of endocrinology.

[9]  L. Heinemann,et al.  How to Assess the Quality of Glucose Clamps? Evaluation of Clamps Performed With ClampArt, a Novel Automated Clamp Device , 2015, Journal of diabetes science and technology.

[10]  S. Mudaliar,et al.  Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects , 2014, Diabetes Care.

[11]  T. Heise,et al.  Steady‐state pharmacokinetics and glucodynamics of the novel, long‐acting basal insulin LY2605541 dosed once‐daily in patients with type 2 diabetes mellitus , 2014, Diabetes, obesity & metabolism.

[12]  J. M. Beals,et al.  Contrasting weight changes with LY2605541, a novel long‐acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM , 2014, Diabetes, obesity & metabolism.

[13]  N. Sattar,et al.  Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks? , 2013, Diabetologia.

[14]  J. Rosenstock,et al.  Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes , 2013, Diabetes Care.

[15]  J. Rosenstock,et al.  A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes , 2012, Diabetes Care.

[16]  J. Holst,et al.  Assessment of hepatic insulin action in obese type 2 diabetic patients. , 2001, Diabetes.

[17]  K. Petersen,et al.  Mechanism of impaired insulin-stimulated muscle glucose metabolism in subjects with insulin-dependent diabetes mellitus. , 1997, The Journal of clinical investigation.

[18]  R. Rizza,et al.  Assessment of insulin action in insulin-dependent diabetes mellitus using [6(14)C]glucose, [3(3)H]glucose, and [2(3)H]glucose. Differences in the apparent pattern of insulin resistance depending on the isotope used. , 1986, The Journal of clinical investigation.

[19]  R. Steele,et al.  Measurement of size and turnover rate of body glucose pool by the isotope dilution method. , 1956, The American journal of physiology.